{"url_path":"/sec/pvct/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/315545/0001493152-26-022950-index.html","accession_number":"0001493152-26-022950","cik":"0000315545","ticker":"PVCT","issuer_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/315545/0001493152-26-022950-index.html","primary_entity_key":"0000315545","primary_entity_name":"PROVECTUS BIOPHARMACEUTICALS, INC."},"word_count":200,"has_tables":true,"body_markdown":"**ITEM\n6. EXHIBITS.**\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n31.1*\n \n[Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).](ex31-1.htm)\n\n \n \n \n\n31.2*\n \n[Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).](ex31-2.htm)\n\n \n \n \n\n32**\n \n[Certification of Principal Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 (Section 906 Certification).](ex32.htm)\n\n \n \n \n\n101.INS*\n \nInline XBRL Instance Document\n– the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL\ndocument.\n\n \n \n \n\n101.SCH*\n \nInline XBRL Taxonomy Extension\nSchema Document.\n\n \n \n \n\n101.CAL*\n \nInline XBRL Taxonomy Extension\nCalculation Linkbase Document.\n\n \n \n \n\n101.LAB*\n \nInline XBRL Taxonomy Extension\nLabel Linkbase Document.\n\n \n \n \n\n101 PRE*\n \nInline XBRL Taxonomy Extension\nPresentation Linkbase Document.\n\n \n \n \n\n101.DEF*\n \nInline XBRL Taxonomy Extension\nDefinition Linkbase Document.\n\n \n \n \n\n104*\n \nCover Page Interactive\nData File (formatted as Inline XBRL and contained in Exhibit 101)\n\n \n\n*\nFiled herewith.\n\n**\nFurnished herewith.\n\n \n\n27\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned thereunto duly authorized.\n\n \n\n \n**PROVECTUS BIOPHARMACEUTICALS, INC.**\n\n \n \n\nMay 14, 2026\nBy: \n*/s/\nDominic Rodrigues*\n\n \n \nDominic Rodrigues\n\n \n \nPresident (Principal Executive Officer)\n\n \n \n                                \n\n \nBy:\n*/s/ Heather\nRaines*\n\n \n \nHeather Raines, CPA\n\n \n \nChief Financial Officer (Principal Financial Officer)\n\n \n\n****\n\n28"}